Compare BBIO & HLI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | BBIO | HLI |
|---|---|---|
| Founded | 2015 | 1972 |
| Country | United States | United States |
| Employees | N/A | 2702 |
| Industry | Biotechnology: Pharmaceutical Preparations | Investment Managers |
| Sector | Health Care | Finance |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 12.7B | 10.4B |
| IPO Year | 2019 | 2015 |
| Metric | BBIO | HLI |
|---|---|---|
| Price | $65.93 | $149.43 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 25 | 7 |
| Target Price | $86.33 | ★ $194.29 |
| AVG Volume (30 Days) | ★ 2.8M | 616.4K |
| Earning Date | 05-12-2026 | 05-06-2026 |
| Dividend Yield | N/A | ★ 1.54% |
| EPS Growth | N/A | ★ 41.61 |
| EPS | N/A | ★ 4.74 |
| Revenue | $502,076,000.00 | ★ $2,389,416,000.00 |
| Revenue This Year | $89.45 | $13.77 |
| Revenue Next Year | $73.78 | $12.10 |
| P/E Ratio | ★ N/A | $32.10 |
| Revenue Growth | ★ 126.26 | 24.81 |
| 52 Week Low | $31.77 | $134.41 |
| 52 Week High | $84.94 | $211.78 |
| Indicator | BBIO | HLI |
|---|---|---|
| Relative Strength Index (RSI) | 40.81 | 43.92 |
| Support Level | $61.95 | $146.58 |
| Resistance Level | $68.71 | $184.59 |
| Average True Range (ATR) | 2.84 | 4.39 |
| MACD | -0.25 | -0.48 |
| Stochastic Oscillator | 28.22 | 25.00 |
BridgeBio Pharma is a biotechnology company focused on discovering, developing, testing, and delivering transformative treatments for patients with genetic diseases. The company has four programs in its late-stage pipeline focusing on Mendelian disorders, oncology, and gene therapy. One of its key programs, Attruby (acoramidis), is an orally administered small molecule designed to stabilize tetrameric transthyretin for the treatment of transthyretin amyloid cardiomyopathy.
Houlihan Lokey Inc is an investment bank with expertise in mergers and acquisitions, capital markets, financial restructuring, valuation, and strategic consulting. The firm serves corporations, institutions, and governments world-wide with offices in the United States, Europe, and the Asia-Pacific region. The company operates in three segments. In the Corporate Finance business segment, it provides M&A and capital markets advisory services. Through the Financial Restructuring business segment, the company advises on some of the complex restructurings around the world. The Financial and Valuation Advisory Services business segment provides valuation and financial opinion, and financial and strategic consulting practices in the United States.